Compositions and methods for treating multiple system atrophy (msa)
AssigneeH. Lundbeck A/S
InventorsLotte KJÆRSGAARD, Stefano Zanigni, Jonas Wiedemann, Josefine Nielsen Søderberg, Pekka Kallunki, Louise Buur, Frank Larsen
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of treating early multiple system atrophy (MSA) or MSA-C using anti-alpha synuclein antibodies, such as Amlenetug.
Claims31
1-15. (canceled)
A method of treating multiple system atrophy (MSA) in a human patient, the method comprising intravenously administering an anti-alpha synuclein antibody at a dose of about 2100 mg or about 4200 mg once every 4 weeks to the patient, wherein the antibody is a full length monoclonal human IgG1 antibody which comprises heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:
- 1, 34, and 3, respectively, and light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:
- 4, 5, and 6, respectively.
A method of treating multiple system atrophy (MSA) in a human patient, the method comprising intravenously administering an anti-alpha synuclein antibody at a dose of about 2100 mg or about 4200 mg once monthly to the patient, wherein the antibody is a full length monoclonal human IgG1 antibody which comprises heavy chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:
- 1, 34, and 3, respectively, and light chain CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:
- 4, 5, and 6, respectively.
A method of treating multiple system atrophy (MSA) in a human patient, the method comprising intravenously administering an anti-alpha synuclein antibody at a dose of about 2100 mg or about 4200 mg once every 4 weeks to the patient, wherein the antibody is a human IgG1, kappa antibody which comprises a heavy chain variable domain and a light chain variable domain comprising the amino acid sequences of SEQ ID NOs:
- 31 and 8, respectively.
A method of treating multiple system atrophy (MSA) in a human patient, the method comprising intravenously administering an anti-alpha synuclein antibody at a dose of about 2100 mg or about 4200 mg once monthly to the patient, wherein the antibody is a human IgG1, kappa antibody which comprises a heavy chain variable domain and a light chain variable domain comprising the amino acid sequences of SEQ ID NOs:
- 31 and 8, respectively.
Dependencies are inferred from the claim text.